Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. Sells 6,500 Shares

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 6,500 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,555,402. The trade was a 12.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Edwards Lifesciences Trading Up 0.2 %

EW stock opened at $75.96 on Friday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a market cap of $44.80 billion, a P/E ratio of 10.96, a PEG ratio of 3.64 and a beta of 1.10. The business has a fifty day moving average of $72.51 and a 200-day moving average of $69.36.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. As a group, equities research analysts expect that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Hedge Funds Weigh In On Edwards Lifesciences

Several large investors have recently bought and sold shares of EW. Crowley Wealth Management Inc. acquired a new stake in Edwards Lifesciences during the 4th quarter worth $26,000. Millstone Evans Group LLC bought a new position in shares of Edwards Lifesciences in the 4th quarter worth $29,000. FSA Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the 3rd quarter worth $30,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $30,000. Finally, Prospera Private Wealth LLC bought a new stake in Edwards Lifesciences in the third quarter valued at about $32,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

EW has been the topic of a number of analyst reports. Sanford C. Bernstein raised shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Truist Financial reissued a “hold” rating and issued a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Piper Sandler boosted their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday. JPMorgan Chase & Co. upped their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Finally, Morgan Stanley lifted their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences presently has an average rating of “Hold” and an average target price of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.